Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated
- 1 June 1977
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 55 (3) , 448-451
- https://doi.org/10.1139/y77-064
Abstract
Dipyridamole, which is known to alter platelet function, has also been shown to reduce hypoxic pulmonary vasoconstriction. This latter effect could result from dipyridamole either acting on a platelet-mediated system, or acting directly on pulmonary vascular smooth muscle. To investigate these two possibilities, normal dogs were compared with dogs rendered thrombocytopenic by a platelet antiserum. Compared with the hypoxic pressor response before drug treatment, the hypoxic response following dipyridamole was only 32% as great in the normal dogs and only 38% as great in the thrombocytopenic dogs. Thus, dipyridamole was no less effective in reducing the hypoxic pressor response in the virtual absence of platelets. This supports a direct effect of dipyridamole on pulmonary vascular smooth muscle, which could be mediated by an increase in adenosine levels.This publication has 5 references indexed in Scilit:
- Platelet antiserum inhibits hypoxic pulmonary vasoconstriction in the dogJournal of Applied Physiology, 1976
- PLATELETS ARE NOT ESSENTIAL FOR PULMONARY VASCULAR PRESSOR-RESPONSE TO HYPOXIA1976
- Physiology of the Regulation of Platelet ProductionBritish Journal of Haematology, 1967
- POTENTIATION OF ADENOSINE AND THE ADENINE NUCLEOTIDES BY DIPYRIDAMOLEBritish Journal of Pharmacology and Chemotherapy, 1966
- Morphology and Enumeration of Human Blood PlateletsJournal of Applied Physiology, 1950